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Continuous infusion of vancomycin was evaluated against experimental endocarditis due to heterogeneous
vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Animals were infected with hVISA PC1
(vancomycin MIC, 2 mg/liter) or VISA PC3 (vancomycin MIC, 8 mg/liter) and treated for 5 days with constant
serum levels of 20 or 40 mg/liter. Vancomycin continuous infusion was unsuccessful, as 20 mg/liter was barely
active against PC1 (6 of 13 sterile vegetations) and 40 mg/liter failed against PC3 (2 of 9 sterile vegetations).
Vancomycin is still considered the agent of choice against
infections caused by methicillin-resistant Staphylococcus aureus
(MRSA). Treatment failures associated with the emergence of
MRSA strains expressing reduced susceptibility to vancomycin,
known as vancomycin-intermediate S. aureus (VISA) or heter-
ogeneous VISA (hVISA), are of potential concern (6). More-
over, therapeutic failures have been observed in the treatment
of infections due to MRSA with vancomycin MICs approach-
ing 2 mg/liter (9, 15). To enhance the performance of vanco-
mycin against such infections, some guidelines have recom-
mended targeting trough levels of the drug ranging between 15
and 20 mg/liter (13). However, recent studies reported that
even trough levels exceeding 15 mg/liter did not improve treat-
ment efficacy against MRSA with a borderline vancomycin
MIC of 2 mg/liter (16).
Continuous infusion may be the best approach to maximize
the time-dependent activity of vancomycin, since serum levels
of the drug can be maintained at some multiples of the MIC
for the infecting organism during the entire dose interval (11,
12). Most isolates of hVISA and VISA have vancomycin MICs
of 2 to 8 mg/liter, and vancomycin levels four to five times
above the MIC can be reached in serum during continuous
infusion of the drug.
Here we tested whether such an approach might be more
efficacious than standard intermittent vancomycin administra-
tion against experimental endocarditis due to either of the
well-described clinical isolates hVISA PC1 and VISA PC3
(14). The vancomycin-susceptible MRSA 217 clinical isolate
was included as a control strain. MICs of vancomycin were
determined by broth macrodilution according to the CLSI
guidelines. The bactericidal activities of vancomycin were mea-
sured by time-kill curves with an inoculum of 107 CFU/ml and
antibiotic concentrations similar to levels attained in rats dur-
ing therapy.
Animal experiments were carried out according to Swiss
regulations. The production of catheter-induced aortic vegeta-
tions and the installation of the infusion pump device for the
delivery of vancomycin were performed as described previ-
ously (4, 5). Valve infection was induced 24 h after catheter-
ization by intravenous (i.v.) challenge of the animals with 106
CFU of the test isolates. Groups of rats were treated with
vancomycin by mimicking human treatment with either 1 g of
the drug i.v. given every 12 h or by continuous infusion ensur-
ing constant serum concentrations of 20 or 40 mg/liter. These
concentrations were chosen because they maintained serum
levels of at least four times the MIC for the infecting organisms
and were considered desirable concentrations for treatment of
patients with MRSA or VISA infections (8, 11). Therapy was
started 12 h after bacterial challenge and lasted for 5 days.
Each experiment included a control group of untreated ani-
mals. Control rats were killed at the onset of treatment, and
treated rats were killed 8 h after the end of the last antibiotic
dose. Aortic vegetations were removed and processed for col-
ony counts as previously described (4). To detect a possible
selection for vancomycin-resistant subpopulations in vivo,
0.1-ml samples from each vegetation homogenate from both
control and treatment groups were plated directly onto agar
plates containing 4 mg of vancomycin per liter for MRSA 217
and 8 and 32 mg of vancomycin per liter for hVISA PC1 and
VISA PC3, respectively. These concentrations were equal to 4
times the MIC of the drug for each organism and do not
tolerate bacterial growth, as shown by population analysis (14).
The rates of valve infection of the various groups were com-
pared by Fisher’s exact test. The bacterial counts in vegetations
were compared by unpaired t test or analysis of variance. Only
animals that had received at least 48 h of treatment were taken
into account in the final evaluation. For statistical compari-
sons, culture-negative vegetations were considered to contain 2
log10 CFU/g, the limit of detection. A P value of !0.05 was
considered significant.
The MICs of vancomycin for MRSA 217, hVISA PC1, and
VISA PC3 were 1, 2, and 8 mg/liter, respectively. In time-kill
studies, vancomycin at concentrations similar to peak or
steady-state serum levels produced a "3-log10-CFU/ml loss of
viability by 24 h toward strain 217 but inflicted a !2-log10-
CFU/ml decrease against strains PC1 and PC3.
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The results of a 5-day treatment of experimental endocar-
ditis are presented in Fig. 1. Intermittent vancomycin admin-
istration (peak and trough levels of at least 50 and 10 mg/liter,
respectively) (3) was very active against the vancomycin-sus-
ceptible MRSA 217. No vancomycin-resistant populations
were selected. In contrast, this regimen failed against both
hVISA PC1 and VISA PC3 organisms and selected for variants
with further increased MICs. Against hVISA PC1, continuous
infusion of vancomycin (28.4 # 4.7 mg/liter) was significantly
more effective than sequential treatment (P ! 0.05) but yet
could not sterilize all the valves, and 1 of 6 vegetation cultures
contained variants that grew on plates containing 8 mg/liter of
vancomycin at a frequency of 10$7. Moreover, continuous in-
fusion of vancomycin (42.7 # 4.3 mg/liter) was totally ineffec-
tive against VISA PC3 and selected further resistant variants
of this organism in 2 of 7 infected valves, with a frequency of
mutation of 10$7 as well. No bacteria resistant to higher levels
of vancomycin were detected in vegetation from untreated
controls. Mortality in animals infected with strain 217 after the
intermittent regimen was 8%. Among rats infected with
hVISA PC1 and VISA PC3, mortality rates were 38% and 50%
after intermittent administration and 30% and 22% after con-
tinuous infusion therapy, respectively.
The present study demonstrates that continuous infusion of
vancomycin, at concentrations affording optimal constant se-
rum levels of 10 times the MIC for the infecting organism, was
more effective than standard sequential treatment but rela-
tively not optimal against experimental endocarditis due to
hVISA. In particular, it carried the risk of selecting a more
resistant bacterial subpopulation in situ. Moreover, constant
serum levels of 5 times greater than the MIC were unable to
treat experimental endocarditis due to VISA and even selected
for further resistance. Asseray et al. (1) also reported poor
outcomes of steady-state vancomycin against VISA experimen-
tal endocarditis in rabbits. However, the treatment duration
was limited to 48 h, and the study did not determine the risk of
selection for further resistance. The failure of continuous in-
fusion vancomycin in the present investigation extends this
original observation to hVISA and especially to a more pro-
longed treatment period. Moreover, it shows that vancomycin
failure may be attributed not only to poor bactericidal activity
but also to the enrichment of less susceptible microbial sub-
populations.
Thus, globally, these results do not support the theoretical
arguments in favor of the use of continuous infusion vancomy-
cin against hVISA and VISA infections. These data, together
with the possible risk of nephrotoxicity associated with the
maintenance of steady-state levels of !20 mg/liter (7, 10),
suggest that there may be no clinical benefit to using continu-
ous infusion of vancomycin to treat hVISA and VISA infec-
tions in humans. Vancomycin in combination with other agents
(2) or alternative therapies with novel antistaphylococcal com-
pounds should be considered for infections caused by S. aureus
with reduced susceptibility to vancomycin.
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